Aspirin

Treatment for Ischemic Heart Disease

Typical Dosage: 75-100mg daily

Effectiveness
85%
Safety Score
80%
Clinical Trials
527
Participants
500K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
80
DangerousModerateSafe
Treatment Details
Dosage Range
75-100mg daily
Time to Effect
immediate
Treatment Duration
lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
40(Treat 40 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
200(Treat 200 patients to see 1 additional serious adverse event)
Confidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10
Monitoring:$50
Side Effect Mgmt:$20
Total Annual:$80
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$5,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$114
Comparison vs No treatment
Cost Difference
+$80/year
More expensive
QALY Difference
+1.00 QALYs
Better outcomes
Dominance
No dominance
Aspirin Outcomes

for Ischemic Heart Disease

Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+70%
Common Side Effects
Gastrointestinal bleeding
+1%
Dyspepsia
+10%

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
2 active trials recruiting for Aspirin in Ischemic Heart Disease

Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization

NCT05347069RECRUITINGPHASE4
View Study
2.89K participants
INTERVENTIONAL
Kyoto, Japan
Started: Jun 14, 2022

Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial

NCT05320926RECRUITINGNA
View Study
3.74K participants
INTERVENTIONAL
Seoul, South Korea
Started: Jul 26, 2022
Completed Clinical Trials
15 completed trials for Aspirin in Ischemic Heart Disease

Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease

NCT02370680COMPLETEDPHASE1
View Study
41 participants
INTERVENTIONAL
Baltimore, United States
Started: Feb 1, 2015

Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels

NCT04097912COMPLETED
View Study
100K participants
OBSERVATIONAL
Multiple Locations, Germany +1 more
Started: Sep 30, 2019

Optimum Platelet Inhibition After Coronary Bypass Surgery

NCT00262275COMPLETEDNA
View Study
INTERVENTIONAL
Cambridge, United Kingdom
Started: Jul 1, 2002

Aspirin Resistance in Coronary Artery Disease

NCT00753935COMPLETEDEARLY_PHASE1
View Study
92 participants
INTERVENTIONAL
Nashville, United States
Started: Jun 1, 2006

Optimal Duration of Clopidogrel in Second-Generation Drug-Eluting Stents

NCT03056118COMPLETEDPHASE4
View Study
1.37K participants
INTERVENTIONAL
Started: May 2, 2011

Chronic Kidney Disease (CKD) Platelet Study

NCT03649711COMPLETEDPHASE3
View Study
76 participants
INTERVENTIONAL
Little Rock, United States +1 more
Started: Nov 1, 2018

Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial

NCT00041938COMPLETEDPHASE3
View Study
2.31K participants
INTERVENTIONAL
Tucson, United States +63 more
Started: Oct 1, 2002

Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation

NCT03198741COMPLETEDPHASE4
View Study
783 participants
INTERVENTIONAL
Shenyang, China
Started: Jul 13, 2017

Aspirin Withdrawal in Non-ischaemic Cardiomyopathy Study

NCT01534026COMPLETEDPHASE4
View Study
12 participants
INTERVENTIONAL
Melbourne, Australia
Started: Mar 1, 2012

SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3

NCT04418479COMPLETEDPHASE4
View Study
5.51K participants
INTERVENTIONAL
Seoul, South Korea
Started: Aug 10, 2020

Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation

NCT00822536COMPLETEDPHASE4
View Study
1.8K participants
INTERVENTIONAL
Paris, France
Started: Jan 1, 2009

Platelet Drug Trial in Coronary Disease Progression

NCT00000496COMPLETEDPHASE3
View Study
INTERVENTIONAL
Started: Dec 1, 1979

Effects of Low Dose Aspirin Pre-treatment on Platelet Activation Undergoing Off-pump Coronary Artery Bypass Surgery

NCT02209909COMPLETEDNA
View Study
48 participants
INTERVENTIONAL
Seoul, South Korea
Started: Jul 1, 2014

Aspirin-Myocardial Infarction Study (AMIS)

NCT00000491COMPLETEDPHASE3
View Study
INTERVENTIONAL
Started: Oct 1, 1974

Physicians' Health Study

NCT00000500COMPLETEDPHASE3
View Study
INTERVENTIONAL
Started: Sep 1, 1981
Showing 20 of 529 total trials